CI-39

CI-39 is an antiviral natural product. CI-39 is an NNRTI (non-nucleoside reverse transcriptase inhibit) antiviral agent with an EC50 of 3.40 µM and an CC50 of >30 µM for wild type HIV-1. CI-39 inhibits HIV-1 RT DNA polymerase and ribonuclease H activitiessup[1].

Signaling Pathways >> Anti-infection >> HIV

Research Areas >> Infection

HIV-1 (WT):3.40 μM (EC50)

HIV-1 (WT):>30 μM (CC50)

CI-39 (0-100 µM) inhibits HIV-1 RT DNA polymerase and ribonuclease H activities with EC50s of 7.20, >30 µM, respectively[1]. CI-39 shows antiviral activities with EC50s of 3.37, 3.00, 2.41, 3.08, 2.14, 3.27, 3.19, 4.07 µM for VSVG/HIV-1wt, VSVG/HIV-1RT-K103N, VSVG/HIV-1wtRT-K103N, VSVG/HIV-1RT-K1RT-Y181C, VSVG/HIV-1RT-K1RT-K103N,Y181C, VSVG/HIV-1RT-K103N,Y181C, VSVG/HIV-1RT-L100I,K103N, VSVG/HIV-1RT-Y188L, VSVG/HIV-1RT-K103N,G190A, VSVG/HIV-1RT-K103N,V108I, respectively[1].

[1]. Xu C, et al. Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root. Eur J Med Chem. 2020 Mar 1;189:112071.